Furthermore, the introduction of GLP1RAs enabled a reduction or suspension of concomitant insulin therapy in, respectively, 61 and 22% of individuals, thereby decreasing the risk of hypoglycemia and eliminating an additional factor negatively impacting body weight. The gene discussed is INS; the disease is Hypoglycemia.